Volume 109, Issue 7 pp. 633-638
Research Article

Compliance with National Comprehensive Cancer Network guidelines in the use of radiation therapy for extremity and superficial trunk soft tissue sarcoma in the United States

Sanjay P. Bagaria MD

Sanjay P. Bagaria MD

Department of Surgery, Mayo Clinic Florida, Jacksonville, Florida

Search for more papers by this author
Jonathan B. Ashman MD, PhD

Jonathan B. Ashman MD, PhD

Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, Arizona

Search for more papers by this author
Larry C. Daugherty MD

Larry C. Daugherty MD

Department of Radiation Oncology, Mayo Clinic Florida, Phoenix, Arizona

Search for more papers by this author
Richard J. Gray MD

Richard J. Gray MD

Deparment of Surgery, Mayo Clinic, Phoenix, Arizona

Search for more papers by this author
Nabil Wasif MD

Corresponding Author

Nabil Wasif MD

Deparment of Surgery, Mayo Clinic, Phoenix, Arizona

Correspondence to: Nabil Wasif, MD, FACS Consultant, Department of Surgery, Mayo Clinic in Arizona, 5777 E Mayo Blvd, Phoenix, AZ 85255. Fax: 480-342-2867. E-mail: [email protected]Search for more papers by this author
First published: 24 January 2014
Citations: 26
This work was presented in part at the American Society of Clinical Oncology (ASCO) Quality Care Symposium, November 1–2, 2012, San Diego, USA.
The authors have no financial disclosures or conflicts of interest.

Abstract

Background

We sought to examine adherence to National Comprehensive Cancer Network guidelines for use of radiation therapy (RT) in patients with soft tissue sarcoma (STS) in the United States.

Methods

The surveillance, epidemiology, and end results cancer registry was queried to identify patients undergoing surgery for truncal and extremity STS from 2004 to 2009.

Results

Of 5,075 patients, 50% received RT. Although routine RT is not recommended for Stage I patients, 25% still underwent RT. Even though routine RT is recommended for Stage II and III tumors, only 60% underwent RT. On multivariate analysis predictors of RT included age <50 years (OR 1.57, 95% CI 1.28–1.91), malignant fibrous histiocytoma histology (OR 1.47, 95% CI 1.3–1.92), T2 classification (OR 1.88, 95% CI 1.60–2.20), and G3 (OR 6.27, 95% CI 5.10–7.72). Patients with Stage III STS who received RT showed improved disease specific survival at 5 years compared to those who did not, 68% versus 46%, P <0.001.

Conclusions

Underuse of RT is seen for a significant proportion of patients undergoing treatment for STS in the United States. More effort needs to be directed towards compliance with appropriate treatment recommendations, perhaps by regionalizing sarcoma care or remote multidisciplinary tumor boards. J. Surg. Oncol 2014; 109:633–638. © 2014 Wiley Periodicals, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.